TrendRadars > News > Novartis offloads neurodevelopmental disorder asset to small Swiss biotech
Novartis offloads neurodevelopmental disorder asset to small Swiss biotech
Novartis offloads neurodevelopmental disorder asset to small Swiss biotech,A small Swiss biotech said it will buy a Novartis cocaine use disorder drug candidate for up to $270 million and will test it in a Phase III clinical trial. The biotech, known as Stalicla, declined to disclose who is behind the financing, other than saying a non-dilutive partner will

Novartis offloads neurodevelopmental disorder asset to small Swiss biotech

A small Swiss biotech said it will buy a Novartis cocaine use disorder drug candidate for up to $270 million and will test it in a Phase III clinical trial. The biotech, known as Stalicla, declined to disclose who is behind the financing, other than saying a non-dilutive partner will